The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of ...
BioPharma Dive

Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics

The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...

AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from ...

Inside the NHS hospital trialling psychedelics to treat depression

Since being diagnosed with depression in 1995, Leonie Schneider has been prescribed antidepressants for over 24 years. “To be ...

It looked like I had achieved the American dream, but I lost myself in the process. Psychedelics helped me find a new beginning.

Howard Steinberg was a successful, married businessman until it all fell apart. Experimenting with magic mushrooms helped him ...

Eli Lilly's $3.8bn psychedelics bet is built on British science

Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a ...
Earth.com

People who took psychedelics on the Fourth of July later reported a shift in political attitudes

New research suggests the broader social climate may shape psychedelic experiences and their lasting psychological effects.
Investor's Business Daily on MSN

Eli Lilly trips into red-hot psychedelics space with a big takeover

Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.